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 36 
Abstract 37 
Context: Carney complex (CNC) is an autosomal dominant condition caused, in most 38 
cases, by an inactivating mutation of the PRKAR1A gene, which encodes for the type 39 
1 alpha regulatory subunit of protein kinase A. CNC is characterized by the occurrence 40 
of endocrine overactivity, myxomas and typical skin manifestations. Cushing syndrome 41 
due to primary pigmented nodular adrenocortical disease (PPNAD) is the most 42 
frequent endocrine disease observed in CNC.  43 
Case Description: Here we describe the first case of a patient with CNC and 44 
adrenocorticotropic hormone (ACTH)-dependent Cushing disease due to a pituitary 45 
corticotroph adenoma. Loss-of-heterozygosity analysis of the pituitary tumour revealed 46 
loss of the wild-type copy of PRKAR1A, suggesting a role of this gene in the pituitary 47 
adenoma development. 48 
Conclusion: PRKAR1A loss of function mutations can rarely lead to ACTH-secreting 49 
pituitary adenomas in CNC patients. Pituitary-dependent disease should be 50 
considered in the differential diagnosis of Cushing syndrome in CNC patients. 51 
 52 
 53 
  54 
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Introduction 55 
Carney complex (CNC) is a syndrome characterized by spotty skin pigmentation, 56 
myxomas and endocrine abnormalities. Although several manifestations of this 57 
disease had been reported previously 1, J. Aiden Carney and colleagues were the first 58 
to describe CNC as a distinct entity in 1985 2. Multiple lentigines are the most common 59 
presenting feature, and frequently affect distinct areas such as the lips, the conjunctiva 60 
and the vaginal or penile mucosa 3, 4. Myxomas can occur in various organs, 61 
particularly the heart, breast and skin. The most common endocrine disease observed 62 
in CNC is adrenocorticotropic hormone (ACTH)-independent Cushing syndrome 63 
secondary to primary pigmented nodular adrenocortical disease (PPNAD) 4. Other 64 
CNC-related endocrine disorders include growth hormone (GH) excess and 65 
hyperprolactinemia secondary to pituitary tumours or hyperplasia, thyroid and 66 
testicular tumours, mostly represented by large cell calcifying Sertoli cell tumours 67 
(LCCSCT) 3, 4 . 68 
In the majority of the cases, CNC is caused by inactivating mutations in the PRKAR1A 69 
gene (17q24.2) coding for the type 1 alpha regulatory subunit of the cAMP-dependent 70 
protein kinase A (PKA) 5. PKA plays a pivotal role in various cellular functions such as 71 
DNA replication, cell growth, proliferation and differentiation and is believed to act as 72 
a tumour suppressor gene via loss of the wild-type allele in affected tissues 6, 7. Most 73 
of the previously described PRKAR1A mutations lead to premature stop codons and 74 
subsequent degradation of the mutant mRNA by nonsense mediated mRNA decay 8. 75 
Inactivating PRKAR1A mutations result in excess PKA signalling in affected tissues 76 
driving the tumorigenic process 7, 9. 77 
 78 
 79 
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Case Presentation and Results 80 
A 31 year-old man presented at our Endocrine Clinic with typical signs of Cushing 81 
syndrome. His physical exam revealed moon face, abdominal obesity, skin atrophy 82 
and pronounced red striae on the abdomen, upper arms and thighs; BMI was 27.1 83 
kg/m2. He had multiple junctional nevi, particularly on his torso. His previous medical 84 
history included surgical removal of the left testicle due to a large cell calcifying Sertoli 85 
cell tumour at the age of four and pilonidal sinus surgery at the age of 24. At the age 86 
of 25, the patient suffered a syncope while playing soccer. Echocardiography revealed 87 
myxomas in both atria with a 35 cm left atrial myxoma protruding through the mitral 88 
valve which necessitated surgical removal. His appearances and previous clinical 89 
history were highly suggestive of CNC 2, 3. 90 
The laboratory work up revealed markedly elevated urinary free cortisol (769 µg/24h, 91 
reference: 2.5-213.7 µg/24h) and increased basal ACTH (106 pg/ml, 23.3 pmol/l, 92 
reference: <46 pg/ml, <10.1 pmol/l; CLIA, Siemens Immulite2000). Morning serum 93 
cortisol was 11.4 µg/dl (314 nmol/l, reference: <1.8 µg/dl, 50 nmol/l) after a 1 mg 94 
overnight dexamethasone suppression test. Consecutive low and high dose 95 
dexamethasone suppression tests (40.5 mg dexamethasone daily for two days 96 
followed by 4x2 mg dexamethasone for two more days) did not result in adequate 97 
suppression of morning serum cortisol levels (basal: 24.2 µg/dl (668 nmol/L), after 48h: 98 
14.0 µg/dl (386 nmol/l), after 96h: 19.0 µg/dl (524 nmol/l)). Corticotrophin releasing 99 
hormone (CRH) test failed to further stimulate his already elevated ACTH levels. The 100 
rest of his pituitary function tests were normal. These results were consistent with 101 
ACTH-dependent Cushing syndrome but not with primary pigmented nodular 102 
adrenocortical disease (PPNAD), a form of ACTH-independent Cushing syndrome 103 
commonly observed in CNC patients 3, 10. Due to the lack of cortisol suppression 104 
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following the high dose dexamethasone suppression test and the absence of ACTH 105 
increase following CRH administration, we suspected ectopic ACTH production as the 106 
reason for hypercortisolism in this patient. Subsequent 18F-fluorodeoxyglucose (18F-107 
FDG) positron emission tomography combined with computed tomography (PET/CT) 108 
as well as 18F-dihydroxyphenylalanine (18F-DOPA) PET/CT did not show any lesions 109 
that would have qualified as a source for ectopic ACTH production. Therefore, inferior 110 
petrosal sinus (IPS) sampling was performed and showed a significant central to 111 
periphery ACTH ratio as well as lateralization to the left (Table 1), strongly suggesting 112 
the pituitary as the origin of the autonomous ACTH production. Magnetic resonance 113 
imaging (MRI) of the sellar region showed a 46 mm left paramedian lesion, compatible 114 
with a pituitary microadenoma (Figure 1a,b), whereas MRI of the adrenal glands was 115 
unremarkable. The left paramedian pituitary tumour was resected by transsphenoidal 116 
surgery and histopathology confirmed a corticotroph adenoma with a Ki-67 labelling 117 
index of 7% (Figure 1c,e). Immunohistochemistry for ACTH was positive (Figure 1d), 118 
while other pituitary hormones, including GH and prolactin were not expressed within 119 
the tumour. Following surgery, morning ACTH was 6.0 pg/ml (1.32 pmol/l) and serum 120 
cortisol 4.1 µg/dl (113 nmol/l). Due to mild symptoms of adrenal insufficiency, the 121 
patient received low-dose hydrocortisone replacement (10 mg/day). In addition, the 122 
clinical signs of Cushing syndrome regressed over time, in keeping with disease 123 
remission. More than seven years after surgery, the patient remains free of signs and 124 
symptoms suggestive of a relapse of hypercortisolism.  125 
 As the patient’s clinical phenotype was compatible with CNC, mutation analysis of the 126 
PRKAR1A gene was undertaken. This revealed a previously described heterozygous 127 
germline mutation in exon 2 (c.109C>T; p.Gln37Ter) that generates a premature stop 128 
codon 5, confirming the diagnosis of CNC in this patient. The mutation appeared to 129 
have occurred de novo, as confirmed by the lack of family history and negative genetic 130 
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testing in the patient’s parents. PRKAR1A, which encodes for the type 1 alpha 131 
regulatory subunit of the protein kinase A, has been suggested to act as a tumour 132 
suppressor gene driving tumorigenesis in CNC patients, as previously demonstrated 133 
by loss-of-heterozygosity studies 7. Thus, we extracted DNA from the pituitary tumour 134 
of our patient and performed loss-of-heterozygosity analysis. By Sanger sequencing, 135 
we found a partial loss of the wild-type allele at the level of the mutation in the patient’s 136 
pituitary tumour (Figure 2A). We then performed genotyping for two microsatellite 137 
markers (D17S942 ‒ centromeric, and D17S789 ‒ telomeric to PRKAR1A). While 138 
analysis of D17S942 was uninformative, genotyping for D17S789 confirmed the loss 139 
of the wild-type allele within the tumour (Figure 2B), with an allele peak height ratio of 140 
2.2, in keeping with loss-of-heterozygosity. 141 
 142 
 143 
Discussion 144 
CNC is a rare genetic syndrome with a variety of clinical manifestations 2-4. Inactivating 145 
germline mutations of the PRKAR1A gene represent the most common cause of CNC. 146 
These mutations can be inherited in an autosomal dominant manner and disease 147 
penetrance is almost complete. However, only approximately 70% of CNC patients 148 
have a positive family history, whereas the remaining cases appear to be caused by 149 
de novo mutations 3, 5, as in our patient.   150 
CNC patients can develop several endocrine manifestations, also including pituitary 151 
disease. The most common pituitary tumours in CNC are GH-producing and 152 
sometimes co-secrete prolactin, whereas corticotroph adenomas have not been 153 
previously reported 11. While PRKAR1A mutations do not typically lead to corticotroph 154 
adenomas, we need to keep in mind that CRH receptors type 1 and 2 signal through 155 
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cAMP 12. In addition, at least one case of a corticotroph adenoma has been described 156 
with an activating mutation of GNAS, encoding the regulatory G-protein alpha subunit 157 
13. Such mutations, leading to the constitutive activation of cAMP production, are 158 
responsible for McCune-Albright syndrome and represent common somatic mutations 159 
observed in somatotroph adenomas 14, 15. 160 
Although loss of chromosome 17 has been described as one of the most common 161 
chromosomal alterations associated with corticotroph adenomas 16, mutations of the 162 
PRKAR1A gene have not been previously identified in patients with Cushing disease 163 
17, 18. Our data support that the PRKAR1A mutation played a pathogenic role in the 164 
development of the pituitary corticotroph adenoma in this patient, as it is unlikely, 165 
although not entirely impossible, that, in addition to CNC, this patient had a coincidental 166 
corticotroph adenoma with a somatic loss at the 17q24 locus.  167 
While up to 60% of all CNC patients develop PPNAD and a significant proportion 168 
presents with clinically overt ACTH-independent Cushing syndrome 2, 4, 5, to our 169 
knowledge, this is the first published case of a CNC patient with Cushing disease due 170 
to a corticotroph pituitary adenoma. In our patient, concomitant PPNAD as the reason 171 
for Cushing syndrome was ruled out on the basis of biochemistry and remission of 172 
Cushing syndrome after resection of the pituitary adenoma. In a previously reported 173 
case of a CNC patient with PPNAD, factitious elevation of ACTH levels has been 174 
described, possibly caused by interfering antibodies with ACTH-like activity 19. 175 
However, such possibility seems unlikely in our patient, considering the results of the 176 
IPS showing a significant central to peripheral ACTH ratio and the significant drop of 177 
the ACTH levels following transsphenoidal surgery. We are aware, however, that our 178 
patient has an increased risk for developing Cushing syndrome secondary to PPNAD 179 
during the course of his life, given the high frequency of PPNAD in patients with CNC.  180 
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In summary, we provide the first evidence that PRKAR1A loss-of-function mutations 181 
can be involved in the tumorigenesis of corticotroph pituitary adenomas. Hence, 182 
pituitary-dependent Cushing disease should be considered in the differential diagnosis 183 
of hypercortisolism in CNC patients. 184 
 185 
Methods 186 
Histopathology and immunohistochemistry 187 
The tumour biopsy specimen was fixed in 4.5% neutral buffered formalin, embedded 188 
in paraffin, cut at 5μm and stained with haematoxylin and eosin. Immunohistochemistry 189 
was performed with a streptavidin-biotin-peroxidase complex method. Sections were 190 
stained with monoclonal antibodies for Ki-67 and ACTH (Dako, Agilent Technologies, 191 
Carpinteria, CA) using a Dako AutostainerPlus Link automated immunostainer (Agilent 192 
Technologies). For visualization the Envision FLEX Plus Dako kit (Agilent 193 
Technologies) was used according to the manufacturer’s recommendations. 194 
 195 
Loss-of-heterozygosity studies 196 
Genomic DNA was isolated from the patient blood (Illustra DNA Extraction Kit BACC2, 197 
GE Healthcare, Little Chalfont, UK) and pituitary corticotroph adenoma tissue (QIAamp 198 
DNA FFPE Tissue Kit, Qiagen, Hilden, Germany). An amplicon encompassing the 199 
PRKAR1A c.109C>T mutation was amplified by PCR using the following primers: 5’-200 
GCACGCAGCCTTCGAGAAT-3’ (forward) and 5’-201 
CTCCAACCTCTCAAAGTATTCCCTG-3’ (reverse). The PCR products were 202 
sequenced by Sanger sequencing under standard conditions. Paired blood- and 203 
pituitary tumour-derived DNA samples were genotyped for two microsatellite markers, 204 
D17S942 (centromeric to PRKAR1A) and D17S789 (telomeric to PRKAR1A). The 205 
9 
 
fluorescently tagged PCR products were run on an ABI3730xl (Applied Biosystems, 206 
Warrington, UK), and allele peak heights were measured using the Peak Scanner 207 
Software v1.0 (Applied Biosystems). The ratio of allele peak heights of the normal and 208 
tumour samples was calculated as follows: (peak height of normal allele 2/peak height 209 
of normal allele 1)/(peak height of tumour allele 2/peak height of tumour allele 1). A 210 
value <0.5 or >2 was considered in keeping with loss-of-heterozygosity, as previously 211 
suggested 20. 212 
 213 
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Figure Legends 234 
 235 
Figure 1. MRI images of the brain showing a left-sided pituitary microadenoma (arrows) on 236 
coronal (a) and sagittal (b) views. Histological and immunohistochemical staining of the tumour 237 
shows large adenoma cells with abundant basophilic cytoplasm (haematoxylin-eosin, c), 238 
robust expression of ACTH (d) and a Ki-67 labelling index of 7% (e); 400x magnification. 239 
 240 
Figure 2. Sanger sequencing for the c.109C>T PRKAR1A mutation and microsatellite 241 
genotyping show loss-of-heterozygosity in the corticotroph adenoma. A. Sanger 242 
sequencing showed partial loss of the wild-type allele in the tumour sample, suggesting loss-243 
of-heterozygosity. B. Capillary electrophoresis analysis for the D17S789 microsatellite marker 244 
in blood- and tumour-derived DNA, showing reduction of the wild-type (**) allele compared to 245 
the mutant (*) allele in the tumour sample. The ratio of allele peak heights was 2.2, confirming 246 
the loss-of-heterozygosity. 247 
 248 
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